NAARDEN, Netherlands & WALTHAM, Mass. & BARCELONA, Spain–(BUSINESS WIRE)– #ALS–Prilenia Therapeutics B.V. and Ferrerii today announced the presentation of new data and PREVAiLS study updates at the upcoming Northeast Amyotrophic Lateral Sclerosis (NEALS) Consortium 2026 annual meeting in Florida. In a new post hoc analysis of a sub-group of 36 participants with definite or probable ALS (El Escorial Criteria) who are within 18 months from first onset of disease symptoms from the Phase 2 HEALEY Platf
